Literature DB >> 4790563

Relative incidence of phlebitis caused by continuous intravenous infusion of cephapirin and cephalothin.

A Z Lane, J G Taggart, R L Iles.   

Abstract

In a single-blinded study, two groups of 10 healthy subjects were given cephapirin or cephalothin by continuous intravenous infusion for 5 days, 0.5 g every 6 hr for the first day and then 1.0 g every 6 hr for 4 days. Eight of the cephalothin subjects and two of the cephapirin subjects developed phlebitis. Phlebitis was more severe in the cephalothin group and developed more rapidly, necessitating vein changes six times more often than in the cephapirin group. The less irritating properties of cephapirin demonstrated in this study indicate it may be the more useful cephalosporin analogue for intravenous therapy.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4790563      PMCID: PMC444297          DOI: 10.1128/AAC.2.3.234

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  LABORATORY AND CLINICAL EVALUATION OF A NEW ANTIBIOTIC--CEPHALOTHIN.

Authors:  M TURCK; K N ANDERSON; R H SMITH; J F WALLACE; R G PETERSDORF
Journal:  Ann Intern Med       Date:  1965-08       Impact factor: 25.391

2.  Clinical and in vitro evaluation of cephapirin: a new parenteral cephalosporin.

Authors:  S J Bodner; M G Koenig
Journal:  Am J Med Sci       Date:  1972-01       Impact factor: 2.378

3.  Cephapirin: clinical, pharmacological, and microbiological studies.

Authors:  S Jameson; M C McHenry; R A VanOmmen; T L Gavan; D G Vidt; D A Butler
Journal:  Del Med J       Date:  1971-11

4.  Laboratory studies with a new cephalosporanic acid derivative.

Authors:  D R Chisholm; F Leitner; M Misiek; G E Wright; K E Price
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

5.  Treatment of bacterial endocarditis with cephalothin.

Authors:  J J Rahal; B R Meyers; L Weinstein
Journal:  N Engl J Med       Date:  1968-12-12       Impact factor: 91.245

6.  Clinical manifestations of chancroid.

Authors:  G Storey
Journal:  Br J Urol       Date:  1970-12

7.  Experiences with cephalothin.

Authors:  R L Perkins; S Saslaw
Journal:  Ann Intern Med       Date:  1966-01       Impact factor: 25.391

8.  Cephapirin: in vitro antibacterial spectrum.

Authors:  J Axelrod; B R Meyers; S Z Hirschman
Journal:  Appl Microbiol       Date:  1971-11

9.  Clinical and in vitro evaluation of cephapirin, a new cephalosporin antibiotic.

Authors:  J L Bran; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

  9 in total
  7 in total

1.  Comparison of phlebitis produced by cephapirin and cephalothin.

Authors:  A S Cross; E C Tramont
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

2.  Comparative incidence of phlebitis due to buffered cephalothin, cephapirin, and cefamandole.

Authors:  S Berger; E C Ernst; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

Review 3.  Newer beta-lactam antibiotics.

Authors:  J M Hamilton-Miller; W Brumfitt
Journal:  Infection       Date:  1974       Impact factor: 3.553

4.  Treatment of pneumonia and other serious bacterial infections with cephapirin.

Authors:  H G Robson; M I Bowmer
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

5.  Comparison of thrombophlebitis associated with three cephalosporin antibiotics.

Authors:  W T Siebert; E L Westerman; J D Smilack; M W Bradshaw; T W Williams
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

6.  Bacampicillin, Ampicillin, Cephalothin, and Cephapirin levels in human blood and interstitial fluid.

Authors:  J S Tan; S J Salstrom
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

7.  Double-blind controlled comparison of phlebitis produced by cephapirin and cephalothin.

Authors:  J Carrizosa; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.